Clinical trial NCT04801940: HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)
Official title: HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID): a National Platform Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Covid19
Lead sponsor: Cambridge University Hospitals NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: University of Liverpool
name: Cambridge University Hospitals NHS Foundation Trust (joint Sponsor)
name: University of Cambridge
First posted: 2021-03-17
Enrollment: 2631
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomisation will use equal probability between all active treatments a given patient is eligible for and Standard Care (SC) as the control arm (i.e. a patient that is eligible for two treatments and SC will be randomized 1:1:1 between the three arms).
Primary purpose: TREATMENT

Brief summary: HEAL-COVID is jointly Sponsored by Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge.

The acute effects of COVID-19 are now well described. Evidence is emerging of serious longer-term complications occurring in the convalescent phase of the illness in a significant proportion of patients; particularly cardiovascular and pulmonary complications.

The ill-defined syndrome, "Long COVID" is likely to include a constellation of different conditions traversing post-ICU syndromes, significant cardiopulmonary complications, post-viral syndromes and exacerbations of underlying conditions. Patients have reported a range of longer-term symptoms associated with Long COVID that have significant impacts on their quality of life.

To date, there has been little work evaluating treatments in the convalescent phase of COVID-19. HEAL-COVID aims to evaluate the impact of treatments on longer-term morbidity, mortality, re-hospitalisation, symptom burden and quality of life associated with COVID-19.

The first two treatment arms are Apixaban and Atorvastatin, with further treatment arms to be added at the direction of the UK COVID-19 Therapeutic Advisory Panel (UKCTAP).

Detailed description: BACKGROUND: In December 2019, a cluster of patients with pneumonia of unknown cause was described in Wuhan, China. Named SARS-CoV-2 due to its resemblance to the coronavirus responsible for severe acute respiratory syndrome (SARS-CoV), COVID-19 is the infectious disease caused by SARS-CoV-2. Despite historically unprecedented public health measures, SARS-CoV-2 has rapidly spread across the world. The World Health Organisation (WHO) declared the COVID-19 outbreak a public health emergency of international concern on 30th January 2020.

The acute effects of COVID-19 are now well described. Evidence is emerging of serious longer-term complications occurring in the convalescent phase of the illness in a significant proportion of patients. COVID-19 is a new disease, the natural history of which remains uncertain. Recent data highlight that \~20% of patients develop new or worsened cardiopulmonary symptoms at 40-60-days after hospital discharge. A unique feature of COVID-19 is the high incidence of these cardiovascular and pulmonary complications that may carry long-term implications for morbidity and mortality including venous thromboembolism, persistent lung inflammation, and pulmonary fibrosis; increasingly it appears these may not be confined to the acute phase of the illness, but rather may also occur during the convalescent phase of the illness, thus providing a major contribution to the ill-defined syndrome "Long COVID".

"Long COVID" is likely to include a constellation of different conditions traversing post-ICU syndromes, significant cardiopulmonary complications, post-viral syndromes and exacerbations of underlying conditions. Patients have reported a range of long-term symptoms associated with Long COVID that have significant impact on their quality of life. Though there have been effective acute treatments, there has been little work evaluating longer-term treatment aimed at reducing longer-term complications. To investigate the role of medium-term convalescent treatment targeting known and emerging complications, an adaptive platform trial will enrol patients at the point of hospital discharge from across centres in the UK.

OBJECTIVES: HEAL-COVID is an adaptive platform trial design to provide reliable evidence on the efficacy of post-hospitalisation treatments to improve longer-term clinical outcomes from COVID-19.

In early 2021, when the trial commenced, there were no treatments being assessed in randomised controlled trials targeting the post-hospital phase of COVID-19. Longer-term outcomes for COVID-19 are currently unclear, but early data suggest a significant burden of mortality and morbidity. In this situation, even treatments with only a moderate impact on survival or on hospital resource use are worthwhile. Therefore, the focus of HEAL-COVID is the impact of candidate treatments on mortality and the need for rehospitalisation.

The primary objective is to determine whether interventions in the post-hospital (convalescent) phase of COVID-19 improve longer-term mortality/morbidity outcomes.

The secondary objectives of HEAL-COVID are to evaluate treatment-specific and patient reported outcomes of COVID-19 and their response to intervention, as well as to estimate the cost-effectiveness of treatments.

ELIGIBILITY AND RANDOMISATION: The HEAL-COVID trial aims to recruit 877 patients per active arm and an equal number of matched controls based on sample size calculations described further in the publicly available trial protocol (www. heal-covid.net). All patients or a representative must provide written, informed consent before any study procedures occur and must meet all eligibility criteria.

ADAPTIVE DESIGN: New therapeutic arms will be commenced on the recommendation of the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP), in discussion with the Chief Medical Officer for England, if approved by the Chief Investigator/Sponsor. New treatments will be added to the platform by recruiting additional participants to the study.

Interim analyses will be undertaken once 181 events have been observed across both arms in the comparison. The Independent Data \& Safety Monitoring Committee (IDSMC) may recommend that the treatment arms be discontinued for lack of benefit, or safety reasons.

SIMPLICITY OF PROCEDURES: To facilitate collaboration, even in hospitals that suddenly become overloaded, patient enrolment (via a secure web-based randomisation and data capture system) and all other trial procedures are greatly streamlined. Informed consent is simple and data entry is minimal. Randomisation via the internet is simple and quick, at the end of which the allocated treatment is displayed on the screen and can be printed or downloaded. Follow-up information is collected via routinely collected data.

Eligibility criteria: Inclusion criteria:

* greater than or equal to 18 years of age.
* hospitalised with estimated hospital discharge within 5 days.
* SARS-CoV-2 infection associated disease (laboratory confirmed SARS-CoV-2 infection) on this hospital admission.
* written informed consent obtained from participant or participant's legal representative.

Exclusion criteria:

* known hypersensitivity to trial medication (patient will be excluded from specific arm).
* long-term pre-hospital administration of trial medication (patient will be excluded from specific arm).
* previous medical history of significant complication with trial medication or trial medication drug class.
* medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial.
* participant not expected to survive 14 days from hospital discharge.

The presence of any of the following will preclude participant inclusion in the Apixaban arm:

* active clinically significant bleeding.
* Childs-Pugh C, or worse, chronic liver disease
* known pregnancy or breast-feeding
* coagulopathy: INR greater than 1.7 or platelet count below 70
* lesion or condition considered by the investigator as a significant risk factor for major bleeding. This may include recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.
* concomitant treatment following discharge with any other anticoagulant agent, including but not limited to unfractionated heparin, low molecular weight heparins (e.g. enoxaparin, dalteparin), heparin derivatives (e.g. fondaparinux), and other oral anticoagulants (e.g. warfarin, rivaroxaban, dabigatran).

The presence of any of the following will preclude participant inclusion in the Atorvastatin arm:

* Childs-Pugh C, or worse, chronic liver disease
* unexplained persistent elevations of serum transaminases exceeding five times the upper limit of normal.
* known pregnancy or breast-feeding.
* treatment with the hepatitis C antivirals lecaprevir/pibrentasvir, ciclosporin or HIV protease inhibitors.
* serum creatine kinase concentration exceeding 10 times the upper limit of normal.

Primary outcomes:
measure: Hospital free survival.
timeFrame: 12 months.
Secondary outcomes:
measure: All-cause mortality
timeFrame: 12 months
measure: Hospital readmission after discharge from index hospital admission
timeFrame: 12 months
measure: Suspected Serious Adverse Reactions
timeFrame: 12 months
measure: FACIT-Fatigue
timeFrame: 12 months
measure: Modified MRC Dyspnoea Scale
timeFrame: 12 months
measure: COVID-19 core outcome measure for recovery
timeFrame: 12 months
measure: Patient Health Questionnaire-2 (PHQ-2)
timeFrame: 12 months
measure: Generalized Anxiety Disorder-2 (GAD-2)
timeFrame: 12 months
measure: PTSD Checklist (PCL-2)
timeFrame: 12 months
measure: Quality of life using the EQ5D-5L
timeFrame: 12 months
measure: Intervention tolerability using the FACT-GP5
timeFrame: 12 months
measure: Additional disease specific systemic symptoms
timeFrame: 12 months
Other outcomes:
measure: Incremental cost-effectiveness
timeFrame: 12 months.
Locations:
city: Cambridge
country: United Kingdom
facility: Addenbrookes Hospital
Study officials:
affiliation: University of Cambridge
name: Charlotte Summers
role: PRINCIPAL_INVESTIGATOR
References: